000 04713nlm1a2200529 4500
001 656904
005 20231030041449.0
035 _a(RuTPU)RU\TPU\network\23384
090 _a656904
100 _a20171220a2017 k y0engy50 ba
101 0 _aeng
102 _aNL
135 _adrcn ---uucaa
181 0 _ai
182 0 _ab
200 1 _a4-Aroyl-3-hydroxy-5-phenyl-1H-pyrrol-2(5H)-ones as N-formyl peptide receptor 1 (FPR1) antagonists
_fL. N. Kirpotina, I. A. Shchepyotkin, A. I. Khlebnikov [et al.]
203 _aText
_celectronic
300 _aTitle screen
320 _a[References: p. 131-132 (55 tit.)]
330 _aFormyl peptide receptors (FPRs) are expressed on a variety of leukocytes and play important roles in inflammation. Thus, FPR antagonists may represent novel therapeutics for modulating innate immunity and treating inflammatory diseases. Previously, 1H-pyrrol-2(5H)-ones were reported to be potent and competitive FPR1 antagonists. In the present studies, 42 additional 1H-pyrrol-2(5H)-one analogs were evaluated for FPR1 antagonist activity. We identified a number of novel competitive FPR1 antagonists that inhibited N-formylmethionyl-leucyl-phenylalanine (fMLF)-induced intracellular Ca2+ mobilization in FPR1-transfected HL60 cells and effectively competed with WKYMVm-FITC for binding to FPR1 in FPR1-transfected RBL cells. The most active pyrroles inhibited human neutrophil Ca2+ flux, chemotaxis, and adhesion to human epithelial cells, with the most potent being compounds 14 (4-benzoyl-1-hexyl-3-hydroxy-5-(4-hydroxy-3-methoxyphenyl)-2,5-dihydro-1H-pyrrol-2-one) and 17 (4-benzoyl-5-(2,5-dimethoxyphenyl)-3-hydroxy-1-(2-methoxyethyl)-2,5-dihydro-1H-pyrrol-2-one). In addition, these FPR1 antagonists inhibited fMLF-induced phosphorylation of extracellular signal-regulated kinases (ERK1/2) in FPR1-RBL cells, differentiated HL-60 cells, and human neutrophils. Most of the antagonists were specific for FPR1 and did not inhibit WKYMVM/WKYMVm-induced intracellular Ca2+ mobilization in FPR2-HL60 cells, FPR3-HL60 cells, or interleukin 8-induced Ca2+ flux in human neutrophils. Moreover, molecular modeling showed that the active pyrroles had a significantly higher degree of similarity with the FPR1 antagonist pharmacophore template as compared to inactive analogs. Thus, the 4-aroyl-3-hydroxy-5-phenyl-1H-pyrrol-2(5H)-one scaffold represents an important backbone for the development of novel FPR1 antagonists and could provide important clues for understanding the molecular structural requirements of FPR1 antagonists.
333 _aРежим доступа: по договору с организацией-держателем ресурса
461 _tBiochemical Pharmacology
463 _tVol. 142
_v[P. 120-132]
_d2017
610 1 _aэлектронный ресурс
610 1 _aтруды учёных ТПУ
610 1 _aantagonist
610 1 _aformyl peptide receptor
610 1 _aneutrophil
610 1 _amolecular modeling
610 1 _aантагонист
610 1 _aформил-пептиды
610 1 _aпирролы
610 1 _aнейтрофилы
610 1 _aмолекулярное моделирование
701 1 _aKirpotina
_bL. N.
_gLiliya Nikolaevna
701 1 _aShchepyotkin
_bI. A.
_cdoctor-biophysicist
_cleading researcher of Tomsk Polytechnic University, candidate of medical science
_f1962-
_gIgor Aleksandrovich
_2stltpush
_3(RuTPU)RU\TPU\pers\37358
701 1 _aKhlebnikov
_bA. I.
_cChemist
_cProfessor of Tomsk Polytechnic University
_f1963-
_gAndrey Ivanovich
_2stltpush
_3(RuTPU)RU\TPU\pers\33927
701 1 _aRuban
_bO. I.
_gOlga Ivanovna
701 0 _aGe Yunjun
701 1 _aYe
_bR. D.
_gRichard
701 1 _aKominsky
_bD. J.
_gDouglas
701 1 _aQuinn
_bM. T.
_gMark
712 0 2 _aНациональный исследовательский Томский политехнический университет (ТПУ)
_bУправление проректора по научной работе и инновациям (НРиИ)
_bЦентр RASA в Томске
_bЛаборатория изучения механизмов нейропротекции (Лаб. ИМН)
_h7608
_2stltpush
_3(RuTPU)RU\TPU\col\21815
712 0 2 _aНациональный исследовательский Томский политехнический университет (ТПУ)
_bИнститут физики высоких технологий (ИФВТ)
_bКафедра биотехнологии и органической химии (БИОХ)
_h6810
_2stltpush
_3(RuTPU)RU\TPU\col\18693
801 2 _aRU
_b63413507
_c20201103
_gRCR
856 4 _uhttps://doi.org/10.1016/j.bcp.2017.07.004
942 _cCF